Zanubrutinib plus venetoclax for relapsed CLL or SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests how well zanubrutinib (a targeted pill) combined with venetoclax (another targeted pill) works for adults with CLL/SLL that came back or progressed after prior treatment. It may help by stopping cancer cells through two different pathways, aiming to shrink disease and improve blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed CLL or SLL, and your prior treatment history fits the study’s relapse/progression rules.
- You must be able to start treatment because your CLL/SLL either relapsed after prior therapy and now needs treatment.
- You must match one of the study cohorts based on what you’ve taken before (a BTK inhibitor vs a BCL-2 inhibitor) and your response to it.
- You must be age 18 or older.
- Your general condition should be good enough (ECOG 0–2).
- Your blood and organ test results must meet safety thresholds (including enough platelets and acceptable liver/kidney function), and you must use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This Phase 2 trial tests a combination of three medicines to treat chronic lymphocytic leukemia (CLL) that has not been treated before and where the goal is to achieve very low remaining disease. It may help some people stay in remission longer, but eligibility depends on your age, organ function, and prior treatments.
This study tests a combination of two oral medications, venetoclax and zanubrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see if this combination is safe and effective, either as a first treatment or after a previous treatment.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
This Phase 2 trial studies whether combining acalabrutinib and venetoclax can shrink or control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or did not respond to prior treatment. It may help by attacking the cancer using two different medicines together.
Hear when a new Chronic Lymphocytic Leukemia (CLL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.